Christopher Steer, Associate Professor at UNSW, shared on LinkedIn:
“I agree Vivek Subbiah and Razelle Kurzrock.
Australian oncologists and their patients applaud the PBAC for this decision.
Clinicians use their skill and expertise to deliver patient centered care utilizing available evidence. These ‘tumor-agnostic’ listings enable this and potentially deliver immunotherapy to patients with tumors that would never see reimbursement under existing rules.”
Title: Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia’s Landmark Tumor-Agnostic Immunotherapy Reimbursement
Authors: Vivek Subbiah, Razelle Kurzrock
You may also be interested in: ESMO 2026: 5 Phase III Immunotherapy Trials to Watch
